Article

Surgical benefits for patients with metastatic kidney cancer compared with target therapy and prognostic factors role to decide treatment tactic

May 2017
European Urology Supplements 16(5):e2178-e2179

DOI:10.1016/S1569-9056(17)31334-9

Authors:

Augustinas Matulevičius

Vilnius University Hospital Santariškių Klinikos

Feliksas Jankevicius

National Cancer Institute,Lithuania

Ausvydas Patasius

National Cancer Institute, Lithuania

ResearchGate has not been able to resolve any citations for this publication.

ResearchGate has not been able to resolve any references for this publication.

Article

Cytoreductive nephrectomy for metastatic renal cell carcinoma

September 2016 · Clinical advances in hematology & oncology: H&O

The incidence of renal cell carcinoma is increasing, with up to one-third of patients presenting with metastatic disease. Combination therapy is used to prolong survival in patients with metastatic renal cell carcinoma, which carries a poor prognosis. Although two pivotal phase 3 trials have demonstrated the efficacy of immunotherapy after cytoreductive nephrectomy for metastatic disease, for ... [Show full abstract] now, targeted therapy has replaced immunotherapy as the preferred systemic treatment in these patients. Two ongoing phase 3 trials are evaluating the role of cytoreductive nephrectomy prior to targeted therapy. Proper patient selection is paramount in achieving successful outcomes. © 2016, Millennium Medical Publishing, Inc. All rights reserved.